Clinical outcomes after re-operative CABG remained constant during the period from 1985 to 2001 despite increasing age and comorbidities among patients. 11:15 a.m.
Background The significance of anemia in patients with acute myocardial infarction (AMI) undergoing primary angioplasty is unknown. We examined the impact of baseline anemia on outcomes after percutaneous coronary intervention (PCI) in AMI from the CADIL-LAC trial. Methods and Results. Anemia by World Health Organization criteria (hematocrit <39% for men and <36% for women) was present in 260 of 2027 randomized patients (12.8%). Patients with vs. without anemia were older, more frequently female, and had a higher prevalence of diabetes and hypertension. At discharge patients with anemia were less likely to be treated with aspirin (91.2% vs. 96%, P=0.0012) and betablockers (67.7% vs. 79.2%, P<0.001). In both males and especially females anemia was associated with increased 30-day and 1-year mortality, and women with anemia had an increased rate of stroke (Table) . One-year rates of reinfarction (2.9% vs. 2.3%) and target vessel revascularization (10.8% vs. 13.7%) were similar in patients with vs. without anemia, respectively. By multivariate analysis lower hematocrit was an independent predictor of 30-day mortality (HR 0.80, P=0.04), one-year mortality (HR 0.83, P=0.02) and disabling stroke (HR 0.39, P=0.004). Conclusions. Anemia at baseline in patients with AMI treated with PCI is common, and is associated with an adverse early and late prognosis. Anemic patients are less likely to be treated with medications proven to improve outcomes after AMI, which adversely affects their survival. 10:00 a.m.
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High Risk Genotypes for Myocardial Infarction Are More Background: African Americans have higher rates of cardiovascular disease than their white counterparts. Whether this greater burden is due to genetic or environmental factors is not known. Recent large case-control studies have identified polymorphisms in connexin-37 (GJA4), plasminogen activator inhibitor-1 (PAI-1), and stromelysin-1 (MMP3) as risk factors for myocardial infarction (MI). We tested the frequency of these polymorphisms in black and white patients to provide new insights into the frequencies of high-risk genotypes in different racial groups. Methods: Genomic DNA from population samples of 95 African Americans (AA) and 95 European Americans (EA) was used for genotyping. DNA containing the polymorphism of interest was amplified using the polymerase chain reaction, followed by genotyping using Pyrosequencing. Results: All three MI-risk genotypes were observed in both populations. All were in Hardy-Weinberg equilibrium. The frequencies of the 'high risk' genotypes were: GJA4 C1019T T/T: AA-20%, EA-7% (p=0.015); PAI-1 -668delG G/G: AA-56%, EA-16% (p<0.001); MMP3 -1171delA A/A: AA-76.9%, EA-24% (p<0.001). In the EA group the likelihood of having 2 or more high-risk genotypes was 3.2%, compared to 47% in the AA group (p<0.001). 8.4% of AA had all three high risk genotypes compared with 0% in the EA group (p=0.004).
Conclusions:
We found higher frequencies of three disease-associated genotypes in AA as compared to EA. Our observed frequency for the PAI-1 polymorphism is consistent with findings of other investigators. This is the first frequency analysis reported for the MMP3 and GJA4 polymorphisms in AA subjects. Importantly, our results also indicate that the presence of multiple high-risk genotypes is significantly more common among AA than EA. These differences in disease-associated genotype frequencies may contribute to racial disparities in cardiovascular disease burden. Further studies are needed to assess both the risk associated with these compound genotypes, as well as their prognostic importance among those with established disease.
10:15 a.m. Background: Re-operative coronary artery bypass grafting (CABG) is an increasing part of current surgical practice. Few data are available regarding the changing profile of patients undergoing re-operative CABG and trends of its outcomes. Methods: Prospectively entered preoperative data of 2770 patients undergoing first re-operative CABG at Emory University Hospitals, from 1985 to 2001, were retrospectively analyzed. Categorical and continuous variables were compared using the chi-square and analysis of covariance, respectively. Results: The mean age was 63.4 years and 85% were male. There was a statistically significant trend over time for patients to be older and sicker by multiple criteria, including presence of diabetes, hypertension, previous myocardial infarction, left ventricular ejection fraction, 3-vessel and left main disease. More operations were performed electively after year 1990. The period between first and re-operative CABG increased significantly, post-procedure length of stay decreased dramatically over time while in-hospital mortality has been stable during the study period (see Table) . Background: A meta-analysis was performed to identify significant differences in outcome between CABG with cardiopulmonary bypass (CPB) and CABG without CPB, "offpump" CABG.
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30-day and 1-year outcomes
Methods: 41 studies that provided 30 day mortality data on off-pump CABG compared to CABG using CPB were analyzed for differences in study design, pre-operative demographics, operative strategy, post-operative morbidity, and survival rates.
Results: In 8 of the 10 studies performed prior to 1996, off-pump CABG was associated with a significant 30 day survival rate disadvantage (odds ratio of survival 0.73; 95% CI 0.56 -0.94; p = 0.02). These 8 studies reported a higher percentage of females undergoing off-pump surgery compared to CABG with CPB . However, off-pump CABG was associated with significant improvements in both 30 day and 15 month average survival rates in the 31 studies performed after 1995, even when there were proportionately more females undergoing off pump surgery compared to CABG with CPB (30 day odds ratio of survival 1.56; 95% CI 1.33-1.84; p = 0.001; 15 month average follow-up odds ratio of survival 1.89, 95% CI 1.24-2.89, p=0.001). Furthermore, post-operative morbidity was significantly less in patients who underwent off-pump CABG versus CABG with CPB after 1995. Commercially available cardiac stabilization devices, which became available in 1996, were uniformly used in 30 of the 31 studies after 1995, but were not consistently employed in the 10 studies performed before 1996 (30/31 v. 0/10, p = 0.00001). These devices could be particularly important in the treatment of women, who have smaller diameter coronary vessels which are more technically challenging to bypass.
Conclusions: Compared to CABG with CPB, off-pump CABG improves both short term and long term survival rates. These improvements in survival rates correlate with the use of commercially available stabilization devices, which may be particularly important in women. Furthermore, off-pump CABG is associated with markedly decreased post-operative morbidity. This suggests that off-pump CABG using commercially available stabilization devices should be the preferred method for surgical coronary revascularization. In-hospital mortality (%) 6.37 6.84 7.50 6.72 0.86
